clinical trial · NCT07317700
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
Chengdu Zenitar Biomedical Technology Co., Ltd·phase3·recruiting·n = 105
MFFlonoltinib 75mgRuxolitinib Phosphate
brief summary
This trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial. Successful trial participants were selected and assigned to either the experimental group or the control group in a 2:1 stratified manner, with the stratification factor being the Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria. Continuously take the test drug/control drug until it meets the withdrawal criteria.
started
Feb 13, 2026
primary completion
Dec 30, 2027
completion
Mar 30, 2028
last updated
Mar 4, 2026
official title
A Randomized, Open-label, Positive-controlled, Parallel-grouped, Multicenter Phase III Clinical Trial on the Efficacy and Safety of Flonoltinib Maleate Tablets in Patients With Intermediate- or High-risk Myelofibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol